West Pharmaceutical Services, Inc. filed an 8-K earnings release on October 29, 2026, reporting third-quarter 2026 financial results and raising its full-year 2026 net sales and adjusted-diluted EPS guidance ranges.

Key Highlights

  • Net sales of $874.5 million in Q3 2026, an increase of 8.7% over the prior-year period, with organic growth of 11.9%, according to the filing.
  • Diluted EPS of $3.02 increased 57.3% and adjusted-diluted EPS of $2.66 increased 35.7% versus the prior-year quarter.
  • Stock repurchases of $231 million in the quarter brought the year-to-date total to $685 million, the company disclosed.
  • Full-year 2026 net sales guidance raised to a range of $3.41 billion to $3.42 billion, up from the previous range of $3.345 billion to $3.380 billion.
  • Full-year 2026 adjusted-diluted EPS guidance raised to a range of $9.38 to $9.48, up from the previous range of $8.85 to $9.05.
  • Board declared a Q4 dividend of $0.26 per share, an increase of 18% over the $0.22 per share paid in the prior quarter, on October 19, 2026.
  • Year-to-date operating cash flow was $403 million and capital expenditures were $125 million through the third quarter.

West Pharmaceutical Services Q3 2026 Segment and Guidance Details

According to the filing, West Pharmaceutical Services (NYSE:WST) reported consolidated net sales of $874.5 million for the three months ended September 30, 2026, compared with $804.6 million in the prior-year period. Gross profit was $347.4 million, representing 40% of net sales, up from $294.3 million, or 37% of net sales, in the year-ago quarter. Operating profit was $267.4 million, or 31% of net sales, versus $167.6 million, or 21% of net sales, in the prior-year period.

The Proprietary Products Segment generated net sales of $728.8 million, a 12.6% increase and a 16.6% increase on an organic basis, the filing stated. Within that segment, High-Value Product (HVP) Components net sales reached $466.7 million, up 19.7% reported and 20.3% on an organic basis, and accounted for 53% of total company net sales. HVP Delivery Devices net sales were $99.1 million, flat on a reported basis but up 26.4% on an organic basis excluding foreign currency effects and the impact of the SmartDose 3.5mL divestiture. Standard Products net sales of $163.0 million increased 2.9% reported and 3.1% organically. The West Vantage Segment reported net sales of $145.7 million, a decrease of 7.3% reported and 6.6% on an organic basis, accounting for 17% of total company net sales.

For the full year 2026, the company disclosed updated capital spending guidance of $215 million to $220 million, reduced from the prior range of $250 million to $275 million. Organic net sales growth guidance was increased to a range of 11.3% to 11.6%, up from the prior range of 10% to 11%. The filing noted that SmartDose 3.5mL generated $55.3 million in net sales in the second half of 2025 and $11.8 million in Q3 2026, and that no additional SmartDose 3.5mL product sales are expected for the remainder of the year. President and CEO Michel Lagarde stated in the release that results "were again led by our High-Value Product (HVP) Components business." The filing also noted the release contains forward-looking statements subject to risks described in the company's regulatory filings.

What Was Disclosed

West Pharmaceutical Services reported Q3 2026 earnings with net sales of $874.5 million and raised full-year 2026 net sales guidance to $3.41 billion to $3.42 billion and adjusted-diluted EPS guidance to $9.38 to $9.48, while repurchasing $231 million of stock in the quarter.